Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Benchmark Statement Prosthetics and Orthotics Services in Lebanon



Lebanese, Syrian and Palestinian people with physical disabilities living in Lebanon are confronted with a variety of barriers that hinder their access to healthcare services especially, rehabilitation services, which include prosthetic and orthotic devices. Furthermore, the absence of a unified and standardized prosthetic and orthotic coverage procedure makes access even more difficult for those individuals.
 
Therefore, the International Committee of Red Cross (ICRC) in Lebanon has worked in close partnership with the Lebanese Ministry of Public Health (MoPH), Lebanese Syndicate of Prosthetics and Orthotics and University of Balamand, with the support of the Rehabskills Limited team, to complete a Benchmark Statement on the Prosthetics and Orthotics Sector in Lebanon (English version).
 
The Benchmark Statement aims at comparing the situation in Lebanon with the World Health Organization (WHO) Standards for Prosthetics and Orthotics as well as making recommendations for its improvement. Consequently, the Benchmark Statement provides a strong foundation that will enable the upgrade of this sector therefore, leading to the establishment of a national strategy for 2030 and regulation of the profession. The Statement covers four main areas of the health system (also known as the four “Ps”): Policy; Products; Personnel and Provision of services. The vision, mission and aims of each ‘P’ will be incorporated into training and mentoring packages that will enable the stakeholders to take ownership and work towards ensuring the sustainability and continuation of the Prosthetics and Orthotics Sector in Lebanon.
 
In April 2021, the ICRC and project partners organized, in collaboration with the Disability Hub, the first online webinar focusing on the Policy area in order to reinforce the visibility and promote the dissemination of the project. The webinar successfully attracted a big number of participants, at a time when health services and systems were and still are severely disrupted in the country due to the Beirut blast, the Covid pandemic, and of course the deteriorating economic situation and political deadlock.



Throughout this year and in 2022, other related online webinars will be organized by the ICRC and project partners to enable the stakeholders to take ownership and work towards ensuring the sustainability and continuation of the Prosthetics and Orthotics Sector in Lebanon.
 
Despite all the difficulties and challenges, Lebanon has taken the first steps on the path of aligning itself with the relevant WHO standards by undertaking this benchmarking process thus, highlighting  its commitment to working towards transforming and improving the provision of prosthetic and orthotic services in the country.
    2
    ...
ATC Name B/G Ingredients Dosage Form Price
R01AB06 TRIOFAN B Xylometazoline HCl - 1mg/ml, Carbocysteine - 10mg/ml Spray, solution 646,388 L.L
P02DA01 TAENIASAN G Niclosamide - 500mg 500mg Tablet 94,709 L.L
P02DA01 TENIADEX G Niclosamide - 500mg 500mg Tablet 70,392 L.L
N06BX06 TRAUSAN G Citicoline - 100mg/ml 100mg/ml Drops solution 807,649 L.L
N06AA09 TRYPTIZOL B Amitryptiline (HCl) - 10mg 10mg Tablet, coated 668,751 L.L
N06AA09 TRYPTIZOL B Amitryptiline (HCl) - 25mg 25mg Tablet, coated 716,716 L.L
N06AA02 TOFRANIL 10 B Imipramine HCl - 10mg 10mg Tablet, sugar coated 579,772 L.L
N06AA02 TOFRANIL 25 B Imipramine HCl - 25mg 25mg Tablet, sugar coated 1,002,123 L.L
N05BA12 TRANQUINAL 0.5 G Alprazolam - 0.5mg 0.5mg Tablet 267,425 L.L
N05BA12 TRANQUINAL 0.5 SUBLINGUAL G Alprazolam - 0.5mg 0.5mg Tablet, sublingual 459,594 L.L
N05AX13 TREVICTA B Paliperidone - 175mg 175mg Injectable suspension, prolonged release 33,673,469 L.L
N05AX13 TREVICTA B Paliperidone - 263mg 263mg Injectable suspension, prolonged release 39,162,480 L.L
N05AX13 TREVICTA B Paliperidone - 350mg 350mg Injectable suspension, prolonged release 48,204,866 L.L
N05AX13 TREVICTA B Paliperidone - 525mg 525mg Injectable suspension, prolonged release 72,306,028 L.L
N03AX18 TREPADIO G Lacosamide - 200mg/20ml 200mg/20ml Injectable solution 9,569,390 L.L
N03AX11 TOPAMAX 25 B Topiramate - 25mg 25mg Tablet, film coated 858,715 L.L
N03AX11 TOPIRATE 25 BENTA G Topiramate - 25mg 25mg Tablet, film coated 671,921 L.L
N03AX11 TORAMAT G Topiramate - 25mg 25mg Tablet, film coated 522,755 L.L
N03AX11 TOPAMAX B Topiramate - 50mg 50mg Tablet, film coated 1,914,976 L.L
N03AX11 TOPIRATE 50 BENTA G Topiramate - 50mg 50mg Tablet, film coated 1,407,835 L.L
N03AX11 TORAMAT G Topiramate - 50mg 50mg Tablet, film coated 1,032,071 L.L
N03AX11 TOPAMAX B Topiramate - 100mg 100mg Tablet, film coated 3,471,145 L.L
N03AX11 TOPIRATE 100 BENTA G Topiramate - 100mg 100mg Tablet, film coated 2,559,700 L.L
N03AX11 TOPIRATE 200 BENTA G Topiramate - 200mg 200mg Tablet, film coated 7,039,175 L.L
N03AF01 TEGRETOL B Carbamazepine - 2% 2% Suspension 456,906 L.L
N02BE01 TYLENOL B Paracetamol - 100mg 100mg Suppository 190,826 L.L
N02BE01 TYLENOL B Paracetamol - 200mg 200mg Suppository 235,172 L.L
N02BE01 TYLENOL B Paracetamol - 350mg 350mg Suppository 239,204 L.L
N02AX02 TRAMAL B Tramadol HCl - 50mg 50mg Capsule 349,399 L.L
N02AX02 TRAMAL 100MG B Tramadol HCl - 100mg/2ml 100mg/2ml Injectable solution 243,235 L.L
    2
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025